Clinical Trial

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-11.
Trial Details
NCT Number NCT07174492
Lead Sponsor AB Science
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 412 participants
Start Date 2026-01-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-03